Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svane

Showing results (761-770 of 811) with videos related to

Pageof 82
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 17, 2025
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanomaMees D Egeler, Sebastian Klobuch, Willemijn S Tak, et al.
Immuno-Oncology Technology|January 13, 2025
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanomaT J Monberg, T Kudling, B Albieri, et al.
Cellular & Molecular Immunology|December 9, 2024
The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signalingMaria Perez-Penco, Mikkel Byrdal, Lucia Lara de la Torre, et al.
Journal of the American Chemical Society|March 22, 2024
Cooperative Effects Drive Water Oxidation Catalysis in Cobalt Electrocatalysts through the Destabilization of IntermediatesBenjamin Moss, Katrine Louise Svane, David Nieto-Castro, et al.
Frontiers in Oncology|April 5, 2024
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposureAnna Spreafico, Eva Muñoz Couselo, Anja Irmisch, et al.
Oncoimmunology|January 17, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanomaSofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, et al.
Nature|January 17, 2020
Tertiary lymphoid structures improve immunotherapy and survival in melanomaRita Cabrita, Martin Lauss, Adriana Sanna, et al.
Oncoimmunology|February 3, 2022
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironmentSimone Kloch Bendtsen, Maria Perez-Penco, Mie Linder Hübbe, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
Nature|April 3, 2020
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaRita Cabrita, Martin Lauss, Adriana Sanna, et al.
Pageof 82

Showing results (761-770 of 811) with videos related to

Sort By:
Pageof 82
European Journal of Cancer (Oxford, England : 1990)|July 17, 2025
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanomaMees D Egeler, Sebastian Klobuch, Willemijn S Tak, et al.
Immuno-Oncology Technology|January 13, 2025
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanomaT J Monberg, T Kudling, B Albieri, et al.
Cellular & Molecular Immunology|December 9, 2024
The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signalingMaria Perez-Penco, Mikkel Byrdal, Lucia Lara de la Torre, et al.
Journal of the American Chemical Society|March 22, 2024
Cooperative Effects Drive Water Oxidation Catalysis in Cobalt Electrocatalysts through the Destabilization of IntermediatesBenjamin Moss, Katrine Louise Svane, David Nieto-Castro, et al.
Frontiers in Oncology|April 5, 2024
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposureAnna Spreafico, Eva Muñoz Couselo, Anja Irmisch, et al.
Oncoimmunology|January 17, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanomaSofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, et al.
Nature|January 17, 2020
Tertiary lymphoid structures improve immunotherapy and survival in melanomaRita Cabrita, Martin Lauss, Adriana Sanna, et al.
Oncoimmunology|February 3, 2022
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironmentSimone Kloch Bendtsen, Maria Perez-Penco, Mie Linder Hübbe, et al.
Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.
Nature|April 3, 2020
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaRita Cabrita, Martin Lauss, Adriana Sanna, et al.
Pageof 82